Strasbourg, France, January 8, 2016 - Transgene SA (Euronext: TNG) today announced its financial reporting dates for 2016:
March 8: 2015 Fiscal Year Results
April 21: First Quarter 2016 Financial Results
May 24: Annual Shareholders' Meeting
September 5: First Half 2016 Financial Results
October 20: Third Quarter 2016 Financial Results
Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at www.transgene.fr.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||3.32 (c)||1.22%||14 979|